Atherogenics Switches Focus For AGI-1067 To Glycemic Control In Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Atherogenics will begin looking for a new partner for the former atherosclerosis treatment, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
AtheroGenics AGI-1067 Development In Diabetes Takes Step Forward
Positive diabetes data, coupled with earlier cardiovascular outcomes, could facilitate approval of AGI-1067 in era of cautious FDA, firm says.
AtheroGenics AGI-1067 Development In Diabetes Takes Step Forward
Positive diabetes data, coupled with earlier cardiovascular outcomes, could facilitate approval of AGI-1067 in era of cautious FDA, firm says.
AtheroGenics Plans Second Phase III Diabetes Study For AGI-1067
Interim analysis from ongoing ANDES trials shows Atlanta firm’s type 2 diabetes candidate significantly reduced hemoglobin A1c reduction.